Drug Database
ME

meningococcal A conjugate vaccine (MenAfriVac)

✓ Approved

Serum Institute of India Pvt. Ltd. · Cell-based Therapies · Cell-based Therapies

What is meningococcal A conjugate vaccine?

meningococcal A conjugate vaccine is a cell-based therapies developed by Serum Institute of India Pvt. Ltd.. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesMenAfriVac
CompanySerum Institute of India Pvt. Ltd.
Drug ClassCell-based Therapies, Vaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved

Therapeutic Indications

meningococcal A conjugate vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsMeningococcal bacteraemia✓ Approved

Related Research Articles

PubMedChemPlusChem2026-08-31

Synergistic Role of Co0 and Lewis Basic Sites for Transfer Hydrogenation of Substituted Nitroarenes by In Situ Hydrogen Generation.

Sharma Anitya A, Ramchiary Dhanmani D, Sharma Devendra D, Kumar Sahil S et al.

Designing green and efficient methods for synthesizing anilines remains a key challenge in synthetic organic chemistry. Hydrogenation of nitro compounds is one of the most significant and widely employed method for producing functionalized anilines. Consequently, designing catalytic systems capable of hydrogenating nitroarenes under environmentally benign and mild reaction conditions remains a challenge. In this regard, a highly efficient CoAl catalyst has been designed for the hydrogenation of nitroarenes to corresponding amines. Various structural, compositional, and morphological characterizations were done to understand the catalyst's structural and surface properties. The as-synthesized catalyst exhibits excellent activity for the transfer hydrogenation of 1-chloro-4-nitrobenzene to 4-chloroaniline, achieving 98% yield at 60 °C within 1.5 h in ethanol. The developed protocol demonstrated excellent activity for wide range of substituted nitroarenes. Structure-activity relationships of CoAl show that basic sites play a crucial role in the transfer hydrogenation. Furthermore, mechanistic investigations reveal that transfer hydrogenation occurs predominantly via a hydroxylamine-mediated pathway. Moreover, the catalyst maintains good catalytic activity up to four consecutive cycles. This method eliminates the need for high-pressure H2, offering a safe strategy for aromatic amine synthesis. The work demonstrates the potential of earth-abundant, non-noble-metal-based heterogeneous catalysts for hydrogenation reactions under environmentally benign conditions.

PubMedExpert review of vaccines2026-08-30

Narrative review of the clinical safety of MenACYW-TT: a quadrivalent meningococcal vaccine conjugated to tetanus toxoid licensed in the US and abroad.

Syrkina Olga O, Bausch-Jurken Mary M, Delgado Arlette A, Jovanovic Jelena J et al.

Routine meningococcal vaccination campaigns have substantially reduced the burden of invasive meningococcal disease in pediatric individuals, leading to relative increases in burden in older age groups. There is a need for safe, effective meningococcal vaccines that can be used across broad age ranges. MenACYW-TT, a quadrivalent tetanus-toxoid-conjugate meningococcal vaccine indicated for individuals aged ≥6 weeks, is one such option. This narrative review summarizes safety data from industry-sponsored pre- and post-licensure clinical trials of MenACYW-TT, including head-to-head studies with active comparators and coadministration studies with routine pediatric vaccines. In >30 trials involving >17,000 participants, MenACYW-TT had a consistent safety profile across all age groups, from infants to older adults. The most frequent side effects were generally mild or moderate and transient; vaccine-related serious adverse events were rare (<0.1%). The safety of MenACYW-TT was comparable to that of other quadrivalent meningococcal conjugate vaccines. Coadministration did not materially affect the safety of MenACYW-TT or routine pediatric vaccines. Immunization remains an essential preventive strategy against the potentially life-threatening and life-altering consequences of invasive meningococcal disease. The favorable benefit-risk profile of MenACYW-TT reinforces the safety of licensed vaccines and can help to counter vaccine hesitancy.

PubMedGeoHealth2026-08-30

How Do Climatic Factors Directly Influence the Incidence and Risk of Meningococcal Meningitis Across the African Meningitis Belt? A Narrative Literature Review.

Cliff Molly M, Diallo Kanny K, Yapi Richard B RB, Tano Axelle B D ABD et al.

Globally, the highest incidence of meningococcal meningitis occurs within the African meningitis belt, spanning 26 countries across sub-Saharan Africa. Meningococcal meningitis incidence is highly seasonal in this region specifically, with outbreaks mostly occurring during the dry season, characterized by low rainfall and atmospheric humidity, high temperature, and increased dust and wind speed. The strong seasonality of meningococcal outbreaks coincides with seasonal variation in climatic factors. This multicollinearity can make it difficult to identify environmental drivers of disease and the mechanisms by which they operate. This review aims to collate existing evidence to better clarify the mechanisms by which climatic variables influence meningococcal meningitis incidence. We examined the impact of dust, wind speed, temperature, rainfall, and land cover on meningococcal meningitis outbreaks. Within the literature, atmospheric dust and wind speed had the strongest statistical association with meningococcal outbreaks and demonstrated greater predictive probability than other climatic variables. However, several climatic factors have demonstrable influences on one another, reflected in the seasonality of meningococcal meningitis. Atmospheric dust can reduce precipitation levels in part through its radiative properties. Decreased rainfall and increasing temperatures can dry out soil, increasing its availability to be uplifted as dust. Alongside, this lower atmospheric humidity increases evaporative demand, leading to faster soil moisture loss and enhanced surface drying. We argue that rainfall, temperature, and land cover variability may act as part of a broader climatic mechanism, increasing atmospheric dust. This increases the incidence and risk of meningococcal meningitis.

PubMedVaccine2026-08-30

Evaluating the potential lifetime health and economic impact of PCV21, an adult-specific 21-valent pneumococcal conjugate vaccine, on invasive pneumococcal disease in adults aged ≥45 years in Spain.

Simuzingili Muloongo M, Fernández-Soberón Silvia S, Yi Zinan Z, Cossrow Nicole N et al.

PCV21, a 21-valent pneumococcal conjugate vaccine (PCV), includes eight unique serotypes not covered by other currently licensed pneumococcal vaccines, and accounts for approximately 79% of IPD cases among adults aged ≥65 years in Spain, compared with 65% for PCV20. This study evaluated the potential lifetime health and economic impact of PCV21 compared with PCV20 vaccination on IPD among adults aged ≥45 years in Spain. A published Markov model estimated the lifetime IPD cases, IPD-related deaths, and associated direct medical costs (2024 Euros) for Spanish adults aged 45-64 and ≥ 65 years vaccinated with either PCV21 or PCV20. A sensitivity analysis assessed the effect of varying inputs on the direct costs averted by PCV21 compared with PCV20. For adults aged 45-64 years, PCV21 was projected to prevent 1590 IPD cases and 134 IPD-related deaths, compared with 1412 cases and 114 deaths prevented with PCV20. Compared with PCV20, PCV21 averted 13% more IPD cases and 17% more IPD-related deaths. The greater reduction in IPD burden translated into €7.3 million in direct medical costs saved with PCV21, 10% higher than the €6.6 million saved with PCV20. Among adults aged ≥65 years, PCV21 was projected to prevent 10,262 IPD cases and 2207 IPD-related deaths, compared with 8243 cases and 1772 deaths prevented with PCV20. Compared with PCV20, PCV21 averted 24% more IPD cases and 25% more IPD-related deaths. The corresponding economic impact was also higher with PCV21, with €1301 million in direct medical costs saved compared with €1044 million for PCV20, representing a 25% greater reduction in costs. In both age groups, PCV21 showed greater health and economic impact associated with IPD compared with PCV20, underscoring the potential benefits of incorporating PCV21 into adult pneumococcal vaccination strategies in Spain.

PubMedMedical mycology journal2026-08-30

Anticandidal Efficacy of a Paste Containing Capric Acid and a Lysozyme-Chitosan Oligosaccharide Conjugate.

Miyanohara Mayu M, Yamada Hidenori H, Nakatsuka Takako T, Okamoto Masaaki M et al.

We report a case series evaluating a novel oral care paste containing capric acid and a lysozyme-chitosan oligosaccharide conjugate (LYZOX). Ten patients with asymptomatic oral Candida colonization performed twice-daily self-care. Clinical eradication was achieved in 80% of cases, including polymicrobial infections involving Candida albicans, Candida glabrata, and Candida parapsilosis. This non-pharmacological approach effectively eliminated Candida species without adverse effects, suggesting a safe, daily preventive strategy for asymptomatic carriers in the maintenance phase of dental treatment.

PubMedKidney medicine2026-08-30

COVID-19 Vaccine Knowledge, Practice, and Attitudes Among Hemodialysis Patients in Egypt, Kenya, and Cameroon: A Multicenter Study.

Elsayed Enass E, Kotb Khaled M KM, Heiba Ahmed A, Elhussini Manal Shaker MS et al.

Patients receiving hemodialysis (HD) are at increased risk of severe coronavirus disease 2019 (COVID-19) and were prioritized for vaccination, yet vaccine hesitancy remains common. We assessed COVID-19 vaccine knowledge, acceptance, and attitudes among patients receiving HD in Egypt, Kenya, and Cameroon and identified factors associated with vaccine acceptance, prior infection, willingness to receive future doses, and postvaccination complications. Multicenter cross-sectional survey study. Between March 2021 and April 2022, 765 patients receiving maintenance HD and 196 non-dialysis controls were recruited from dialysis centers in Egypt, Kenya, and Cameroon. Sociodemographic characteristics, clinical comorbidities, prior COVID-19, sources of vaccine information, and exposure to vaccinated or infected relatives. COVID-19 vaccine acceptance, willingness to receive future doses, prior infection, and post-vaccination complications. Structured questionnaires assessed knowledge, practices, and attitudes toward COVID-19 vaccination. Multivariable logistic regression identified factors independently associated with study outcomes. Vaccine acceptance was lower among patients receiving HD than nondialysis controls (58.2% vs 96.2%). Fear of side effects was the most common reason for refusal (39.3%). Postvaccination complications were less frequent among patients receiving HD (22.3% vs 44.3%). Hesitancy was more common among women, younger participants, and those with comorbidities or no prior COVID-19. Having vaccinated or previously infected relatives was associated with a greater willingness to receive future doses. Cross-sectional design limits causal inference. Nonprobability sampling and unmatched controls may limit generalizability. COVID-19 cases may have been underreported because of limited testing. COVID-19 vaccine hesitancy among patients receiving HD is driven by fear, misinformation, and sociodemographic factors. Targeted education and improved access to reliable vaccine information may help increase uptake in this population.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about meningococcal A conjugate vaccine